У нас вы можете посмотреть бесплатно RECORD: real-world outcomes of darolutamide in non-metastatic CRPC или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, comments on findings from the RECORD study, a real-world evaluation of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC). PSA reductions were consistent with data from the ARAMIS trial (NCT02200614), and treatment was well tolerated. No significant differences in response were observed based on Gleason score, PSA doubling time, or next-generation imaging use, supporting the use of darolutamide in the clinic. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.